Insider Selling: Pyxis Oncology, Inc. (NASDAQ:PYXS) CEO Sells 8,541 Shares of Stock

Pyxis Oncology, Inc. (NASDAQ:PYXS) CEO Lara Sullivan sold 8,541 shares of the business’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $2.10, for a total value of $17,936.10. Following the sale, the chief executive officer now owns 2,403,882 shares of the company’s stock, valued at approximately $5,048,152.20. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Lara Sullivan also recently made the following trade(s):

• On Wednesday, September 13th, Lara Sullivan sold 3,000 shares of Pyxis Oncology stock. The stock was sold at an average price of $2.27, for a total value of $6,810.00.
• On Monday, September 11th, Lara Sullivan sold 20,000 shares of Pyxis Oncology stock. The stock was sold at an average price of $2.27, for a total value of $45,400.00.

Pyxis Oncology Price Performance

Pyxis Oncology stock traded down $0.07 during midday trading on Monday, hitting $2.04. 157,906 shares of the company were exchanged, compared to its average volume of 1,492,791. The company’s fifty day moving average price is $2.39 and its 200-day moving average price is $2.79. Pyxis Oncology, Inc. has a fifty-two week low of $1.10 and a fifty-two week high of $6.92. The company has a market cap of $80.64 million, a PE ratio of -0.72 and a beta of 1.12.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Friday, August 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.24. On average, analysts expect that Pyxis Oncology, Inc. will post -2.13 EPS for the current fiscal year.

Hedge Funds Weigh In On Pyxis Oncology

A number of institutional investors have recently made changes to their positions in PYXS. Bank of New York Mellon Corp raised its position in shares of Pyxis Oncology by 69.0% in the 1st quarter. Bank of New York Mellon Corp now owns 32,589 shares of the company’s stock valued at $132,000 after purchasing an additional 13,305 shares in the last quarter. Citigroup Inc. raised its position in shares of Pyxis Oncology by 7,171.6% in the 1st quarter. Citigroup Inc. now owns 233,129 shares of the company’s stock valued at $942,000 after purchasing an additional 229,923 shares in the last quarter. BlackRock Inc. raised its position in shares of Pyxis Oncology by 1.4% in the 1st quarter. BlackRock Inc. now owns 520,901 shares of the company’s stock valued at $2,104,000 after purchasing an additional 7,053 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Pyxis Oncology by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 526,309 shares of the company’s stock valued at $2,126,000 after purchasing an additional 6,011 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Pyxis Oncology by 55.9% in the 1st quarter. State Street Corp now owns 144,795 shares of the company’s stock valued at $585,000 after acquiring an additional 51,920 shares during the last quarter. 52.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Royal Bank of Canada initiated coverage on Pyxis Oncology in a research report on Tuesday, September 5th. They set an “outperform” rating and a $7.00 price target on the stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.